Nemolizumab-Ilto Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 30 mg/mL
Reference Brands: Nemluvio (USA)
Category:
Derma Drugs
Nemolizumab-ilto is available in Injection
and strengths such as 30 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nemolizumab-ilto is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nemolizumab-ilto can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nemolizumab-ilto injection is a biologic medicine used for the treatment of moderate to severe inflammatory skin conditions. It is administered alone or in combination with other treatments such as topical corticosteroids or calcineurin inhibitors when symptoms are not adequately controlled with topical therapy alone. This targeted treatment option is especially beneficial for patients who continue to experience persistent symptoms despite standard topical management.
Nemolizumab-ilto is also indicated for the treatment of prurigo nodularis, a chronic skin disorder characterized by intense itching and nodular skin lesions. By targeting specific immune pathways involved in itch and inflammation, nemolizumab-ilto helps reduce pruritus and improve skin condition. Its mechanism of action addresses the underlying causes of itch and inflammation rather than only providing symptomatic relief.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing